source
- Bristol Myers reports Phase 2 success for GPRC5D‑directed CAR‑T therapyBristol Myers announced positive Phase 2 results for its GPRC5D‑directed CAR‑T therapy aimed at treating multiple myeloma. The study demonstrated encouraging efficacy signals, adding to the growing…
- Moonwalk Biosciences raises $70M to move RNAi obesity drug MW101 toward first-in-human trials in 2027Moonwalk Biosciences, an obesity drug developer backed by Eli Lilly, announced a $70 million Series B financing. The funding will support its lead RNAi candidate, MW101, which in mouse studies pro…